JP2001516567A - 抗原の免疫原性および抗体の特異性を改善する方法 - Google Patents

抗原の免疫原性および抗体の特異性を改善する方法

Info

Publication number
JP2001516567A
JP2001516567A JP2000511524A JP2000511524A JP2001516567A JP 2001516567 A JP2001516567 A JP 2001516567A JP 2000511524 A JP2000511524 A JP 2000511524A JP 2000511524 A JP2000511524 A JP 2000511524A JP 2001516567 A JP2001516567 A JP 2001516567A
Authority
JP
Japan
Prior art keywords
peptide
hapten
conformation
peptidomimetic
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000511524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516567A5 (https=
Inventor
ジュディス フィッツパトリック，
レジナ レンダ，
Original Assignee
セレックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレックス， インコーポレイテッド filed Critical セレックス， インコーポレイテッド
Publication of JP2001516567A publication Critical patent/JP2001516567A/ja
Publication of JP2001516567A5 publication Critical patent/JP2001516567A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000511524A 1997-09-19 1998-09-18 抗原の免疫原性および抗体の特異性を改善する方法 Pending JP2001516567A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5937897P 1997-09-19 1997-09-19
US9045898P 1998-06-24 1998-06-24
US60/059,378 1998-06-24
US60/090,458 1998-06-24
PCT/US1998/019660 WO1999013907A2 (en) 1997-09-19 1998-09-18 Methods to improve immunogenicity of antigens and specificity of antibodies

Publications (2)

Publication Number Publication Date
JP2001516567A true JP2001516567A (ja) 2001-10-02
JP2001516567A5 JP2001516567A5 (https=) 2006-01-05

Family

ID=26738686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000511524A Pending JP2001516567A (ja) 1997-09-19 1998-09-18 抗原の免疫原性および抗体の特異性を改善する方法

Country Status (6)

Country Link
US (5) US6455047B1 (https=)
EP (1) EP1015028A2 (https=)
JP (1) JP2001516567A (https=)
AU (1) AU749305B2 (https=)
CA (1) CA2303775A1 (https=)
WO (1) WO1999013907A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6710190B1 (en) 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
PT1185524E (pt) * 1999-05-28 2005-04-29 Warner Lambert Co Analogos de gaba substituidos por 3-heteroarilalquilo
GB0031079D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Vaccine
FR2877668B1 (fr) * 2004-11-10 2007-07-06 Gemac Sa Procede de couplage de molecules non immunogenes, compose intermediaire, produit final obtenu et utilisations
WO2009120954A2 (en) * 2008-03-27 2009-10-01 The Scripps Research Institute Nicotine immunoconjugates
US8603828B2 (en) * 2009-11-18 2013-12-10 Bio-Rad Laboratories, Inc. Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
US20160116489A1 (en) * 2014-10-23 2016-04-28 Biomedomics, Inc. Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults
CN106053788A (zh) * 2016-07-21 2016-10-26 苏州博源医疗科技有限公司 一种可替宁均相酶免疫检测试剂及其制备和检测方法
US20190343951A1 (en) * 2017-01-13 2019-11-14 National Research Council Of Canada Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines
BR112019019630A2 (pt) 2017-05-19 2020-04-14 Philip Morris Products S.A. teste diagnóstico para distinguir o status de tabagismo de um sujeito
WO2019094909A1 (en) * 2017-11-13 2019-05-16 Matsfide, Inc. Vaccine development methodology based on an adhesion molecule
KR20210141990A (ko) * 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
CN110642743B (zh) * 2019-10-18 2021-01-01 中国农业大学 硝呋酚酰肼半抗原和人工抗原及其制备方法与应用
CN110724671A (zh) * 2019-10-31 2020-01-24 浙江蓝盾药业有限公司 杂交瘤细胞株1g8、抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647654A (en) 1984-10-29 1987-03-03 Molecular Diagnostics, Inc. Peptides useful in preparing hemoglobin A1c immunogens
CA1339952C (en) * 1984-10-29 1998-07-14 William J. Knowles Immunoassays for denatured protein analytes, particularly hb alc, and monoclonal antibodies thereto
US4727036A (en) 1985-08-08 1988-02-23 Molecular Diagnostics, Inc. Antibodies for use in determining hemoglobin A1c
DE3806198A1 (de) * 1988-02-04 1989-08-17 Boehringer Mannheim Gmbh Immunogen und seine verwendung zur gewinnung von antikoerpern gegen hba(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)c(pfeil abwaerts)
US5045480A (en) * 1989-02-09 1991-09-03 Miles Inc. Gel particles having hapten moieties bound thereto as immunoassay reagent
US5484735A (en) 1989-08-23 1996-01-16 Northwestern University Immunoassay of glycosylated proteins employing antibody directed to reductively glycosylated N-terminal amino acids
US5164504A (en) * 1991-01-16 1992-11-17 Abbott Laboratories Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives
AU661207B2 (en) * 1992-11-17 1995-07-13 Boehringer Mannheim Gmbh Simultaneous determination of HbA1c and haemoglobin variants with a glycation analogus to HbA1c
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2175862A1 (en) * 1995-05-19 1996-11-20 Roberto Sundoro Wu Propoxyphene derivatives for immunoassay reagents
US5929237A (en) * 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay

Also Published As

Publication number Publication date
US20030086939A1 (en) 2003-05-08
AU9496998A (en) 1999-04-05
AU749305B2 (en) 2002-06-20
WO1999013907A2 (en) 1999-03-25
WO1999013907A9 (en) 1999-09-10
US7303750B2 (en) 2007-12-04
US20030113339A1 (en) 2003-06-19
WO1999013907A3 (en) 1999-06-03
CA2303775A1 (en) 1999-03-25
US20030095976A1 (en) 2003-05-22
US20030077287A1 (en) 2003-04-24
US6455047B1 (en) 2002-09-24
EP1015028A2 (en) 2000-07-05
US7335516B2 (en) 2008-02-26
US7147858B2 (en) 2006-12-12

Similar Documents

Publication Publication Date Title
Trier et al. Production and characterization of peptide antibodies
JP2001516567A (ja) 抗原の免疫原性および抗体の特異性を改善する方法
JPH0751087A (ja) 変性タンパク質に対するモノクローナル抗体
US5698197A (en) Monoclonal antibody specific for advanced glycosylation endproducts in biological samples
USRE39138E1 (en) Monoclonal antibody specific for advanced glycosylation endproducts in biological samples
JP2540362B2 (ja) 免疫原及び抗体の取得法
US5955582A (en) Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
JP4318458B2 (ja) ｐａｎ特異的モノクローナル抗体
JP2006115716A (ja) 抗ｃ反応性タンパク質モノクローナル抗体産生細胞ライン、その作製方法、およびそれにより産生されたモノクローナル抗体
US6814951B1 (en) Acetaldehyde and malondialdehyde protein adducts as markers for alcohol liver disease
US5856106A (en) Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
JPH076982B2 (ja) 抗 体
JP2789208B2 (ja) Ｍｈｐｇに対する抗体の製造法
AU726344B2 (en) High fluorescence specific immune enhancing factor and methods of use for same
JPH01153960A (ja) 赤血球凝集アッセイ
Armentano et al. Induction of covalent binding antibodies
JP3849001B2 (ja) 抗−２′−デオキシシチジン抗体並びにその製造及び使用
LT6770B (lt) Nilaparvata lugens pce3 polipeptidas ir jam specifinio poliklonino antikūno gamybos būdas
JPH02176464A (ja) 薬物とタンパクとの結合物
JPS63102700A (ja) ヒトのグリコアルブミンの定量において使用するための抗体
JPS5847257A (ja) 改良された特異抗体の製造法
JPH04225162A (ja) ヒト・オステオカルシンフラグメントに対する抗体
IE882828L (en) Agglutination assay
JPH01258699A (ja) ブラジキニン誘導体およびその定量

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081217